Entera Bio Ltd. (ENTX) Bundle
An Overview of Entera Bio Ltd. (ENTX)
General Summary of Entera Bio Ltd. (ENTX)
Entera Bio Ltd. is a biopharmaceutical company focused on developing oral biologics using its proprietary technology platform. The company was founded in 2009 and is headquartered in Israel.
Company Products and Services
Entera specializes in developing oral delivery technologies for biologics and large molecule drugs. Key product areas include:
- Bone health therapeutics
- Metabolic disease treatments
- Oral delivery technology platform
Financial Performance Overview
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $3.2 million |
| Research & Development Expenses | $12.4 million |
| Net Loss | $14.6 million |
Market Position and Pipeline
Key Pipeline Highlights:
- EB613 - Oral Parathyroid Hormone for Osteoporosis
- EB612 - Oral GLP-1 for Diabetes and Obesity
- Proprietary oral delivery platform for biologics
Company Leadership
| Position | Name |
|---|---|
| Chief Executive Officer | Spiros Jamas |
| Chief Financial Officer | Mayer Slomovic |
Stock Performance
| Stock Metric | 2024 Value |
|---|---|
| NASDAQ Ticker | ENTX |
| Current Stock Price | $1.47 |
| Market Capitalization | $43.2 million |
Mission Statement of Entera Bio Ltd. (ENTX)
Mission Statement of Entera Bio Ltd. (ENTX)
Entera Bio Ltd. (ENTX) mission statement focuses on advancing oral biologic drug delivery technologies to transform patient treatment experiences.
Core Mission Components
| Component | Specific Focus | Quantitative Target |
|---|---|---|
| Innovative Drug Delivery | Oral Biologics Platform | 3 clinical-stage drug candidates |
| Patient-Centric Approach | Non-Invasive Treatment Solutions | Potential 85% patient preference for oral administration |
| Technological Advancement | Proprietary EB Technology | 7 issued patents as of 2024 |
Strategic Mission Objectives
- Develop oral biologics for complex therapeutic areas
- Reduce patient injection dependency
- Minimize treatment complexity
Research and Development Focus
Current R&D investment: $12.4 million in 2023 fiscal year
| Drug Candidate | Therapeutic Area | Development Stage |
|---|---|---|
| EB612 | Osteoporosis | Phase 2 Clinical Trials |
| EB101 | Hypoparathyroidism | Phase 2 Clinical Trials |
Technology Platform Capabilities
Proprietary EB Technology Platform enables oral delivery of large molecule therapeutics
- Molecular weight handling: Up to 50 kDa
- Potential bioavailability improvement: 3-5%
- Enhanced intestinal permeability mechanisms
Vision Statement of Entera Bio Ltd. (ENTX)
Vision Statement of Entera Bio Ltd. (ENTX)
Strategic Vision for Pharmaceutical InnovationEntera Bio Ltd. focuses on developing oral biologics and innovative drug delivery technologies targeting complex medical conditions.
Key Vision Components
Oral Drug Delivery PlatformEntera Bio's vision centers on transforming biological drug delivery through proprietary technological platforms.
| Technology Focus | Current Development Stage |
|---|---|
| Oral Biologics Platform | Advanced preclinical/clinical stage |
| Proprietary Intestinal Permeation Enhancement Technology | Validated in multiple therapeutic areas |
- Osteoporosis treatment
- Parathyroid hormone (PTH) therapies
- Diabetes management
- Rare metabolic disorders
Technology Advancement Metrics
| Parameter | 2024 Status |
|---|---|
| R&D Investment | $8.2 million |
| Patent Portfolio | 12 active patents |
| Clinical Trial Programs | 3 ongoing programs |
Entera Bio aims to establish leadership in oral biologics delivery technologies with innovative solutions for challenging therapeutic areas.
Core Values of Entera Bio Ltd. (ENTX)
Core Values of Entera Bio Ltd. (ENTX) in 2024
Innovation and Scientific ExcellenceEntera Bio Ltd. demonstrates commitment to innovation through its focus on oral peptide and protein drug delivery platform.
| R&D Investment | Patent Portfolio | Research Focus Areas |
|---|---|---|
| $8.2 million (2023) | 12 granted patents | Oral biologic therapeutics |
- Developed proprietary E-QTTM technology platform
- Advanced oral delivery technologies for challenging molecules
- Continuous investment in technological improvements
Commitment to developing innovative therapeutic solutions addressing unmet medical needs.
| Clinical Pipeline | Target Indications | Patient Impact |
|---|---|---|
| 3 active clinical programs | Osteoporosis, Hypoparathyroidism | Improved oral drug delivery |
Strategic collaborations with academic and pharmaceutical research institutions.
- Ongoing collaboration with leading research universities
- Multiple partnership agreements in pharmaceutical development
- Active engagement in scientific conferences and symposiums
Strict adherence to regulatory guidelines and ethical research practices.
| Regulatory Compliance | Ethical Standards | Clinical Trial Transparency |
|---|---|---|
| FDA and EMA compliance | Rigorous research protocols | Registered clinical trials |
Commitment to sustainable research practices and corporate social responsibility.
- Environmentally conscious research methodologies
- Reduction of research waste
- Ethical sourcing of research materials
Entera Bio Ltd. (ENTX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.